Genetic Engineering
Estimating the family and wider societal health economic impacts of genomic therapeutics.
University of Oxford
About the Project A major hurdle to integrating genome-targeted therapies, such as antisense oligonucleotides (ASOs) and CRISPR-based therapies, into routine care is the health technology assessment process and the need to demonstrate cost-effectiveness to agencies such as NICE. In many countries, reimbursement decisions have traditionally focused on narrow measures of economic benefit, with limited consideration of the wider societal impacts of health interventions.
- Location
- Oxford, United Kingdom, United Kingdom
- Deadline
- 1 December 2026
- Funding
- Funded PhD Project (Students Worldwide)